Unlock the value of Qiagen
Davidson Kempner considers Thermo Fisher Scientific’s offer to acquire QIAGEN to severely undervalue the company and will not tender its shares into the offer.
Davidson Kempner considers Thermo Fisher Scientific’s offer to acquire QIAGEN to severely undervalue the company and will not tender its shares into the offer.
Sign-up and stay informed.
We will notify you of any updates via email.